Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGAVE-201 axatilimab dose-ranging study in recurrent or refractory active chronic graft-versus-host disease
2024-512978-99-00Phase 2Authorised
- Sponsor
- Syndax Pharmaceuticals
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of axatilimab in chronic graft-versus-host disease (cGVHD) (3 arms), sponsored by Syndax Pharmaceuticals. Primary endpoint: Overall response rate in the first 6 cycles. Planned start Jul 2021; status: authorised.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2024-512978-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512978-99-00.